Can zapping tumors with surgery or radiation boost lung cancer treatment?
NCT ID NCT06114108
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at people with advanced stage IV non-small cell lung cancer that has spread. After standard therapy (chemo, immunotherapy, or targeted drugs) works well, some will also get surgery or radiation on remaining tumors. The goal is to see if this extra treatment helps keep cancer from growing longer and maintains quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 128 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2023
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients fulfilling all of the following inclusion criteria at screening may be enrolled in the trial. * The inclusion criteria are irrespective from the tumor burden at the time of primary diagnosis before initiation of first line systemic therapy. Treatment of brain metastases upfront or after an induction phase of standard systemic therapy is done according to the standard practice of the treating center. * Adults (18 years or older) * Tissue confirmed, pre-treatment clinical stage IV NSCLC * ECOG performance status ≤ 1 * Patients responding after 3 cycles (4th bridging cycle up until randomization is allowed) or 3 months of first line SoC systemic therapy with PR or SD in restaging imaging, and presenting with (induced) oligometastatic or oligopersistent NSCLC defined as a maximum of 5 residual extracranial, distant metastases * Patients may have up to 5 cranial metastases in addition to the oligoresidual extracranial metastases as long as they are amenable for radiotherapy or surgery. * The primary tumor and all oligopersistent metastases must be amenable for radical LAT (surgery or radiotherapy) * Patients of reproductive age agree to use double contraception during the study * Patient is able to understand trial procedures and is able/willing to adhere to trial procedures as confirmed by signature Exclusion Criteria: The presence of any one of the following exclusion criteria at screening will lead to exclusion of the participant: * Serious concomitant disorder that would compromise patient safety during LAT * Unresolved complications from initial systemic anticancer treatment, higher than CTCAE grade 2 * Metastatic locations such as malignant ascites, malignant pleural or malignant pericardial effusion, diffuse lymphangiosis of skin or lung, diffuse bone marrow metastasis, abdominal masses/abdominal organomegaly, identified by physical exam that is not measurable by reproducible imaging techniques, leptomeningeal carcinomatosis * Women who are pregnant or breast feeding * Patient is currently involved in a trial that either does not permit participation in other trials or would result in excessive patient burden if another trial were joined. In such cases, the co-investigators' team and the Patient Advisory Board will decide on participation on an individual basis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Hôpital Fribourgeois - Hôpital Cantonal
RECRUITINGFribourg, Switzerland
-
Hôpitaux Universitaires Genève HUG
RECRUITINGGeneva, 1205, Switzerland
-
IOSI Ospedale Regionale di Bellinzona e Valli
RECRUITINGBellinzona, 6500, Switzerland
-
Kantonspital Aarau
RECRUITINGAarau, 5001, Switzerland
-
Kantonsspital Graubuenden
RECRUITINGChur, CH-7000, Switzerland
-
Luzerner Kantonsspital
RECRUITINGLucerne, Switzerland
-
Universitätsspital Zürich
RECRUITINGZurich, 8091, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Wearables guide home prehab for older lung cancer patients
- Can immunotherapy outperform chemotherapy for lung cancer?
- Can a cocktail of immune boosters shrink Hard-to-Treat tumors?
- Wearable tech and digital rehab may shorten recovery between lung cancer surgeries
- Can a targeted pill boost lung cancer treatment?
- A new strategy to tame lung cancer Drug's nerve pain?